HYPOTHESIS: A ratio of 3 months of posttherapy to pretherapy 2-[F]fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography (F-FDG PET/CT) standard uptake values (SUVs) predicts progression-free survival after chemoradiation in patients with stages IB2 to IVA cervical cancer. METHODS: This retrospective review included 51 patients who received treatments of daily pelvic radiation and once-weekly cisplatin chemotherapy followed by brachytherapy. Posttherapy confirmatory surgical or cytologic pathology was done a median of 7 days after 3-month F-FDG PET/CT. RESULTS: All 51 patients receiving chemoradiation achieved at least a partial metabolic response (ie, >25% decrease in F-FDG PET/CT SUV) in the expected region of the cervix. A ratio of less than 0.33 for posttherapy to pretherapy F-FDG PET/CT SUVs of the expected area of the cervix was associated with a 35% improvement in 6-month progression-free survival. CONCLUSIONS: In patients with cervical cancer, the 3-month posttherapy F-FDG PET/CT value is an indicator of therapeutic response to chemoradiation and needs further validation in clinical trials.
HYPOTHESIS: A ratio of 3 months of posttherapy to pretherapy 2-[F]fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography (F-FDG PET/CT) standard uptake values (SUVs) predicts progression-free survival after chemoradiation in patients with stages IB2 to IVA cervical cancer. METHODS: This retrospective review included 51 patients who received treatments of daily pelvic radiation and once-weekly cisplatin chemotherapy followed by brachytherapy. Posttherapy confirmatory surgical or cytologic pathology was done a median of 7 days after 3-month F-FDG PET/CT. RESULTS: All 51 patients receiving chemoradiation achieved at least a partial metabolic response (ie, >25% decrease in F-FDG PET/CT SUV) in the expected region of the cervix. A ratio of less than 0.33 for posttherapy to pretherapy F-FDG PET/CT SUVs of the expected area of the cervix was associated with a 35% improvement in 6-month progression-free survival. CONCLUSIONS: In patients with cervical cancer, the 3-month posttherapy F-FDG PET/CT value is an indicator of therapeutic response to chemoradiation and needs further validation in clinical trials.
Authors: Charles A Kunos; Tomas Radivoyevitch; Adam Kresak; Dawn Dawson; James Jacobberger; Bin Yang; Fadi W Abdul-Karim Journal: Int J Gynecol Cancer Date: 2012-11 Impact factor: 3.437
Authors: Charles A Kunos; Robert Debernardo; Jeffrey Fabien; Donald C Dobbins; Yuxia Zhang; James Brindle; Peter F Faulhaber Journal: J Nucl Med Radiat Ther Date: 2011-12-12
Authors: Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati Journal: Gynecol Oncol Date: 2013-04-18 Impact factor: 5.482
Authors: Sasan Partovi; Andres Kohan; Chiara Gaeta; Christian Rubbert; Jose L Vercher-Conejero; Robert S Jones; James K O'Donnell; Patrick Wojtylak; Peter Faulhaber Journal: Am J Nucl Med Mol Imaging Date: 2013-04-09
Authors: John M Floberg; Jin Zhang; Naoshad Muhammad; Todd A DeWees; Matthew Inkman; Kevin Chen; Alexander J Lin; Ramachandran Rashmi; Kay Jayachandran; Brian T Edelson; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby; Stephanie Markovina; Julie K Schwarz Journal: Clin Cancer Res Date: 2021-04-05 Impact factor: 12.531